person · Reporting owner
Globeways Holdings Ltd
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | 10% owner | January 12, 2021 | January 14, 2021 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · 10% owner | July 28, 2022 | August 05, 2022 |
| TCR2 THERAPEUTICS INC.TCRR · Entity 94327 | 10% owner | December 18, 2019 | December 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date January 12, 2021 · Filed January 14, 2021
Jointly reported with Jovan-Embiricos Morana, F2 Vision SCS, F2 Bioscience I 2017 Ltd, F2 MG Ltd, F2 - TPO Investments LLC, F2 Bio TD, LLC, F2 MC, LLC, F2 GC, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,136,525 |
Reported balance
After 2021-01-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-01-12 · Conversion · Acquired 1,136,525 · Balance 1,136,525 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F2: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,912,345 |
Reported balance
After 2021-01-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-01-12 · Conversion · Acquired 2,912,345 · Balance 2,912,345 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F3: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 639,295 |
Reported balance
After 2021-01-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-01-12 · Conversion · Acquired 639,295 · Balance 639,295 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F4: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 455,338 |
Reported balance
After 2021-01-12 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-01-12 · Conversion · Acquired 455,338 · Balance 455,338 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 182,135 |
Reported balance
After 2021-01-12 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-01-12 · Conversion · Acquired 182,135 · Balance 182,135 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 526,937 |
Reported balance
After 2021-01-12 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2021-01-12 · Conversion · Acquired 71,599 · Balance 526,937 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 325,333 |
Reported balance
After 2021-01-12 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2021-01-12 · Conversion · Acquired 143,198 · Balance 325,333 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 71,599 |
Reported balance
After 2021-01-12 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2021-01-12 · Conversion · Acquired 71,599 · Balance 71,599 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F7: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 214,798 |
Reported balance
After 2021-01-12 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2021-01-12 · Conversion · Acquired 214,798 · Balance 214,798 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F8: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 622,175 |
Reported balance
After 2021-01-12 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2021-01-12 · Purchase · Acquired 95,238 · Balance 622,175 F5: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 104,762 |
Reported balance
After 2021-01-12 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2021-01-12 · Purchase · Acquired 104,762 · Balance 104,762 F9: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series Seed Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-01-12 · Conversion · Disposed 8,000,000 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F2: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-01-12 · Conversion · Disposed 20,500,000 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F3: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-01-12 · Conversion · Disposed 4,500,000 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F4: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-01-12 · Conversion · Disposed 3,205,128 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-01-12 · Conversion · Disposed 1,282,051 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-01-12 · Conversion · Disposed 503,988 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2021-01-12 · Conversion · Disposed 1,007,977 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2021-01-12 · Conversion · Disposed 503,988 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F7: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-01-12 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2021-01-12 · Conversion · Disposed 1,511,966 · Balance 0 F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F8: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 112,507 |
Reported balance
Holding disclosure · report date 2021-01-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 112,507 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.
F2: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F6: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F7: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F8: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F9: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Kalaris Therapeutics, Inc.
Report date July 28, 2022 · Filed August 05, 2022
Jointly reported with F2 MG Ltd, F2 - TPO Investments LLC, F2 MC, LLC, F2 Capital I 2020, F2 Bioscience AV 2022 LLC, Globeways Holdings II Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,059,884 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,059,884 F1: Shares held by F2 MG Ltd. ("F2 MG"). Globeways Holdings Ltd. is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Morana Jovan-Embiricos is the founding director of Globeways Holdings Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy F2-TPO Investments, LLC | 668,072 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 668,072 F2: Shares held by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Ltd. is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy F2 MC, LLC | 2,038,583 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,038,583 F3: Shares held by F2 MC, LLC ("F2 MC"). Globeways Holdings II Ltd. is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy F2 Capital I 2020 LLC | 4,193,874 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,193,874 F4: Shares held by F2 Capital I 2020 LLC ("F2 2020"). Globeways Holdings II Ltd. is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy F2 Bioscience AV 2022 LLC | 867,678 |
Reported balance
Holding disclosure · report date 2022-07-28 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 867,678 F5: Shares held by F2 Bioscience AV 2022 LLC ("F2 2022"). Globeways Holdings II Ltd. is the appointed manager of F2 2022 has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2022. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by F2 MG Ltd. ("F2 MG"). Globeways Holdings Ltd. is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Morana Jovan-Embiricos is the founding director of Globeways Holdings Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2: Shares held by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Ltd. is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: Shares held by F2 MC, LLC ("F2 MC"). Globeways Holdings II Ltd. is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: Shares held by F2 Capital I 2020 LLC ("F2 2020"). Globeways Holdings II Ltd. is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5: Shares held by F2 Bioscience AV 2022 LLC ("F2 2022"). Globeways Holdings II Ltd. is the appointed manager of F2 2022 has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2022. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Ltd., and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Ltd. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
TCR2 THERAPEUTICS INC.
Report date December 18, 2019 · Filed December 20, 2019
Jointly reported with Jovan-Embiricos Morana, Globeways Holdings II Ltd, F2 Capital I 2015 Ltd, F2 Captial I 2017 Ltd, F2 MG Ltd, F2 Bioscience II 2017 Ltd, F2 - TPO Investments LLC, F2 BBG LLC, F2 Capital I 2019, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 89,217 |
Reported balance
After 2019-12-18 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2019-12-18 · Sale · Disposed 458 · Balance 89,217 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 191,309 |
Reported balance
After 2019-12-18 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2019-12-18 · Sale · Disposed 2,433 · Balance 191,309 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 82,575 |
Reported balance
After 2019-12-19 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2019-12-19 · Sale · Disposed 6,642 · Balance 82,575 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 155,986 |
Reported balance
After 2019-12-19 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2019-12-19 · Sale · Disposed 35,323 · Balance 155,986 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 713,723 |
Reported balance
After 2019-12-20 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2019-12-20 · Other · Disposed 586,153 · Balance 713,723 F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners. F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 161,024 |
Reported balance
After 2019-12-20 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2019-12-20 · Other · Disposed 13,847 · Balance 161,024 F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners. F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 361,665 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 361,665 F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 432,319 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 432,319 F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 330,238 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 330,238 F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.
F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.
F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,511,966 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 21 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 214,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries C Convertible Preferred Stock · Derivative | 503,988 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 20 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 71,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,007,977 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 19 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 143,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries C Convertible Preferred Stock · Derivative | 503,988 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 18 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 71,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,282,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 17 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 182,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,205,128 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 16 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 455,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 15 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 639,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries A Convertible Preferred Stock · Derivative | 20,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 14 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,912,345 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionSeries Seed Convertible Preferred Stock · Derivative | 8,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 13 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,136,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | PurchaseCommon Stock | 104,762 | $21.00 | $2,200,002.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 104,762 F9 · ownership.nature: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | PurchaseCommon Stock | 95,238 | $21.00 | $1,999,998.00 |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 11 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622,175 F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 214,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 10 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 214,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 71,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 71,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 143,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 325,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 71,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 526,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 182,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 182,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 455,338 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 455,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 639,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 639,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 2,912,345 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,912,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | ConversionCommon Stock | 1,136,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,136,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | OtherCommon Stock | 13,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 161,024 F5 · kind: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners. F6 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | OtherCommon Stock | 586,153 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 713,723 F3 · kind: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners. F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 35,323 | $16.47 | $581,819.26 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 155,986 F2 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 6,642 | $16.47 | $109,403.04 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 82,575 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 2,433 | $17.01 | $41,375.60 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 191,309 F2 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 458 | $17.01 | $7,788.75 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 89,217 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 4,153 | $17.65 | $73,310.83 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,299,876 F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,054 | $17.65 | $18,605.74 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 11 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 330,238 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,381 | $17.65 | $24,378.10 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 10 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 432,319 F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,155 | $17.65 | $20,388.64 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 361,665 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 30,475 | $17.62 | $537,067.02 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,304,029 F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 7,741 | $17.62 | $136,421.19 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 331,292 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 10,135 | $17.62 | $178,611.13 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 433,700 F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 8,479 | $17.62 | $149,427.11 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 362,820 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 75,067 | $17.65 | $1,325,015.12 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,334,504 F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 19,070 | $17.65 | $336,606.48 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 339,033 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 24,966 | $17.65 | $440,677.36 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 443,835 F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 19:09 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 20,886 | $17.65 | $368,660.87 |
DisclosureSEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 371,299 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:36 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 2,085 | $15.16 | $31,602.55 |
DisclosureSEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,409,571 F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:36 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 530 | $15.16 | $8,033.26 |
DisclosureSEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 358,103 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:36 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 693 | $15.16 | $10,503.87 |
DisclosureSEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 392,185 F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 18:36 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 580 | $15.16 | $8,791.12 |
DisclosureSEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 392,185 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 5,516 | $17.31 | $95,489.68 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,411,656 F6 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,401 | $17.31 | $24,253.27 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 11 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 358,633 F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,835 | $17.31 | $31,766.42 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 10 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 469,464 F4 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 351 | $17.31 | $6,076.30 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 89,675 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 683 | $17.31 | $11,823.69 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 174,871 F2 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,535 | $17.31 | $26,573.00 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 392,765 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 197,343 | $17.94 | $3,539,425.64 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,417,172 F6 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 50,134 | $17.94 | $899,173.34 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 360,034 F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.